In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex, with a price target of $74.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Celldex’s promising developments and strategic advancements. The company is making significant progress with its barzolvolimab program, particularly in the treatment of chronic spontaneous urticaria (CSU). The Phase 3 program is on track to complete enrollment by Summer 2026, and a Phase 3b long-term extension study is planned, indicating a robust pipeline and commitment to advancing treatment options.
Moreover, the recent data from the Phase 2 CSU study, presented at a major conference, demonstrated impressive efficacy and tolerability, with a notable percentage of patients achieving a complete response and well-controlled disease. This level of durability off-treatment is unprecedented in CSU therapies, setting Celldex apart from competitors. Additionally, the upcoming Phase 3 program for chronic inducible urticaria (CIndU) and the anticipated data from the CDX-622 trials further bolster the company’s growth potential. These factors, combined with a manageable cash burn and strategic planning, underpin Slutsky’s positive outlook on Celldex’s stock.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 9.2% and a 36.87% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and DBV Technologies SA – American.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $43.00 price target.